Sanofi sets up its Global R&D Operations Hub in China

| By | China, R&D, Sanofi
0
269

Sanofi, a French multinational pharmaceutical company, is launching a Global R&D Operations Hub with a specialized focus on digitalization and big data analysis in Chengdu, Sichuan province, China. The new R&D operations hub confirms China as the third pillar of Sanofi Global Clinical Sciences and Operations, joining facilities in France and the United States.

With an investment of €66 million, the Hub will support the clinical research and development of Sanofi’s innovative drugs by focusing on the management of global multi-center clinical trials data and files. Bringing together global data and analysis, the Hub will accelerate the availability of trial results, from Phase I to Phase IV. The Hub will take advantage of local talents to further strengthen Sanofi’s digital capabilities.

The Chengdu Hub will target diseases that affect millions of people across our therapeutic areas: diabetes and cardiovascular diseases, vaccines, oncology, immunology and inflammation, rare diseases, multiple sclerosis and neurology. It will leverage global cutting-edge biological technology for polypeptides, gene therapy, monoclonal antibodies and multi-specific antibodies. The Hub plans to recruit 300 local pharmaceutical research and development professionals by 2020.

Sanofi China, established in 1982 with headquarters in Shanghai, has a wide range of businesses covering pharmaceuticals and human vaccines (Sanofi Pasteur).

With the China R&D Center and the Asia-Pacific R&D Center in Shanghai, Sanofi possesses an overall R&D capability, from drug targets to clinical trials, and has been focusing on frequently occurring diseases like liver diseases, diabetes, cancers and cardiovascular diseases in China and the Asia-Pacific region.

SOURCE: prnewswire
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.